Investment Rating - The report provides an "Outperform" rating for multiple companies in the healthcare sector, including BeiGene, JD Health, WuXi Biologics, and others, indicating a positive outlook for these stocks [1]. Core Insights - The macro and industry environment is improving due to the resolution of policy uncertainties, the release of significant clinical data, and a resurgence in global M&A activity, leading to a notable increase in investor sentiment towards innovative drugs for 2026 [4][11]. - In oncology, the PD-1/VEGF dual antibody approach is transitioning from "mechanism validation" to "clinical and industrial resonance," with multiple global Phase III trials underway, expected to catalyze approvals and data releases within the year [5][17]. - The metabolic sector is seeing growth in the cash-pay market for GLP-1 drugs, driven by limited insurance coverage and high out-of-pocket costs, prompting companies to enhance accessibility through direct sales and pricing adjustments [6][25]. - In the autoimmune space, there is a growing concentration risk among major products from multinational corporations (MNCs), with new antibody platforms expected to yield significant data in 2026, potentially leading to new business development opportunities [7]. - The central nervous system (CNS) investment focus remains on advancing Aβ monoclonal antibody treatments, with key data expected to open up early intervention market opportunities [9]. Summary by Sections Oncology - The PD-1/VEGF dual antibody's clinical and industrial certainty is strengthening, with major companies conducting multiple global Phase III trials across high-value indications [17]. - The Pan-RAS precision therapy is entering a realization phase, with key Phase III data expected in 2026 for pancreatic cancer and NSCLC [22]. Metabolic - The cash-pay market for GLP-1 drugs is expanding due to limited insurance coverage, with companies like Eli Lilly and Novo Nordisk adopting different direct-to-consumer strategies to enhance accessibility [25][26]. - Small nucleic acid therapies are expected to upgrade treatment paradigms, showing competitive data in weight loss and safety profiles when combined with GLP-1 [30]. Autoimmune - MNCs are increasingly reliant on a few blockbuster products, with structural opportunities arising from new antibody platforms expected to report data in 2026 [7]. - The trend towards oral formulations in autoimmune diseases is gaining traction, offering advantages in adherence and competitive differentiation [7]. CNS - The focus in CNS remains on Aβ monoclonal antibody treatments, with advancements expected to shift treatment towards earlier intervention populations [9]. - New delivery methods, such as systemic administration of small nucleic acids, are being explored as complementary approaches [9].

Core Viewpoint - The report from交银国际 indicates a slight decrease in the proportion of domestic investors holding pharmaceutical stocks through the Hong Kong Stock Connect since the fourth quarter of last year, while foreign investment has increased, particularly in innovative drugs and leading CXO companies benefiting from demand recovery [1] Group 1: Investment Trends - Domestic investors' holdings in pharmaceutical stocks via Hong Kong Stock Connect have slightly decreased [1] - Foreign investors have increased their positions, particularly in innovative drug companies and leading CXO firms [1] Group 2: Investment Recommendations - The report suggests focusing on differentiated platforms such as small nucleic acids, long-acting formulations, invivo CAR-T, and new generation ADC/XDC, as well as disease areas like autoimmune, metabolic, and CNS [1] - The pharmaceutical sector is expected to maintain a stable upward trend this year, although short-term volatility may occur [1] Group 3: Stock Selection Criteria - Investors are advised to examine company fundamentals and valuations to identify undervalued stocks, such as 三生制药, 和黄医药, and 劲方医药, which have rich catalysts not yet reflected in their valuations [1] - CXO segment leaders, like 药明合联, are expected to benefit from a favorable downstream environment and improved financing conditions [1] - Sub-sectors such as hospitals, medical devices, and diagnostics are anticipated to see regulatory uncertainties gradually easing along with positive policy expectations [1]

Core Viewpoint - The Hang Seng Healthcare Index has declined by 3.3% this week, underperforming the market, with a slight decrease in domestic investors' holdings of pharmaceutical stocks through the Hong Kong Stock Connect since the fourth quarter of last year, while foreign investment has increased [1] Group 1: Market Performance - The Hang Seng Healthcare Index has experienced a cumulative drop of 3.3% this week [1] - Domestic investors' holdings of pharmaceutical stocks via the Hong Kong Stock Connect have slightly decreased [1] - Foreign investment in the sector has increased, particularly in innovative drugs and leading CXO companies benefiting from demand recovery [1] Group 2: Investment Recommendations - The company suggests focusing on differentiated platforms such as small nucleic acids, long-acting formulations, invivo CAR-T, and new generation ADC/XDC in the pharmaceutical business development this year [1] - The sector is expected to maintain a stable upward trend this year, although short-term volatility may occur [1] - Investors are advised to examine company fundamentals and valuations to identify undervalued stocks, such as 3SBio (01530), Hutchison China MediTech (00013), and Genscript Biotech (02595) [1] - CXO segment leaders like WuXi AppTec (02268) may benefit from a favorable downstream environment and improved financing conditions [1] - Sub-sectors such as hospitals, medical devices, and diagnostics may see regulatory uncertainties easing along with positive policy expectations [1]

截至2026年2月5日 09:41，中证港股通医药卫生综合指数(930965)上涨0.32%，成分股银诺医药-B上涨 10.07%，药明康德上涨2.73%，海吉亚医疗上涨2.65%，再鼎医药上涨2.13%，四环医药上涨1.89%。港 股医药ETF(159718)下跌0.22%，最新报价0.92元。 消息面上，政策持续支持医药产业，国家药监局称，"十五五"期间将大力支持生物制造产业创新发展。 港股医药ETF紧密跟踪中证港股通医药卫生综合指数，中证港股通医药卫生综合指数从港股通范围内选 取50只流动性较好、市值较大的医疗卫生行业上市公司证券作为指数样本，以反映港股通范围内医药卫 生上市公司证券的整体表现。 数据显示，截至2026年1月30日，中证港股通医药卫生综合指数(930965)前十大权重股分别为药明生 物、百济神州、信达生物、康方生物、京东健康、石药集团、中国生物制药、翰森制药、药明康德、三 生制药，前十大权重股合计占比64.57%。 港股医药ETF(159718)，场外联接(平安中证港股医药ETF联接A：019598；平安中证港股医药ETF联接 C：019599；平安中证港股医药ETF联接E：024544 ...

冲高回落后探底回升，出现了止跌企稳的继续，截止午盘，恒生指数小涨0.21%。银行涨幅居前，恒生 医疗、大消费紧随其后，恒生科技逆势绿盘。 恒生科技高开低走，盘中一度下跌2.63%，截止午盘下跌0.97%。其中快手大跌4.35%，百度集团下跌 3.54%，腾讯控股下跌3.09%，比亚迪股份、阿里巴巴、美团、小米集团等股跌幅均在1%上方。 内容只是个人观点，仅供参考，不作为投资依据！欢迎关注交流，互相学习、共同探讨！ 恒生医疗高开低走后探底回升，截止午盘上涨0.72%。其中石药集团大涨4.15%，药明生物上涨3.12%， 百济神州上涨2.78%；三生制药、康方生物、京东健康等股逆势回撤。 恒生银行跳空高开后维持在高位窄幅盘整，截止午盘上涨1.2%。其中渣打银行上涨3.84%，汇丰控股上 涨2.45%，中银香港上涨2.33%，大新银行、重庆银行、大新金融等股涨幅均在1%上方。 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 截至月份: | 2026年1月31日 | | | | 狀態: 新提交 | | --- | --- | --- | --- | --- | --- | | 致：香港交易及結算所有限公司 | | | | | | | 公司名稱: | 三生制药（「本公司」） | | | | | | 呈交日期: | 2026年2月4日 | | | | | | I. 法定/註冊股本變動 | | | | | | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 (註1) | 是 | | 證券代號 (如上市) | 01530 | 說明 | | | | | | 法定/註冊股份數目 | 面值 | | 法定/註冊股本 | | | --- | --- | --- | --- | --- | --- | | 上月底結存 | 50,000,000,000 | USD | 0.00001 | USD | 500,000 | | 增加 / 減少 (-) | | | | USD | | | 本月底結存 | 50,000,000,000 | USD ...

港股通数据统计周报 2026.01.26-2026.02.01 | 分析师： | 蒋开来 | | --- | --- | | 中央编号： | BWL381 | | 联系电话： | 852-6430 1060 | | 邮箱： | jiangkl@cnzsqh.hk | 1 目录 2 l 港股通前十大净买入/卖出公司 l 港股通净买入/卖出行业分布 l 港股通前十大活跃个股 l 港股通与南下资金介绍 港股通前十大净买入/卖出公司 3 港股通本周前十大净买入公司（2026.01.26-2026.02.01） | 序号 | 证券代码 | 证券简称 | 行业 | 港股通持股变动数 | 净买入金额（亿元） | | --- | --- | --- | --- | --- | --- | | 1 | 9992.HK | 泡泡玛特 | 可选消费 | 13440803 | 30.05 | | 2 | 0700.HK | 腾讯控股 | 信息技术 | 4621172 | 28.00 | | 3 | 1810.HK | 小米集团-W | 信息技术 | 49988528 | 17.75 | | 4 | 2628.HK | 中国人寿 | ...

Group 1 - The report highlights that the leading CDN service provider, Wangsu Technology, is expected to benefit significantly from the recent price increases announced by major overseas cloud service providers due to rising AI training demands, indicating a potential pricing restructuring in the global cloud computing market [4][5]. - Wangsu Technology has a strong global presence with over 2,800 edge nodes across more than 90 countries, and its core CDN and edge computing business generated revenue of 2.177 billion yuan, accounting for 62.35% of total revenue in the first three quarters of 2025 [5][6]. - The company's cybersecurity business is emerging as a key profit source, achieving revenue of 1.031 billion yuan in the first three quarters of 2025, with a gross margin of 78.90%, indicating a strong synergy with its CDN client base [6][7]. Group 2 - The report notes that Tesla's Q4 2025 earnings report revealed a total revenue of $94.827 billion, a 3% year-over-year decline, with a net profit of $3.794 billion, down 46% year-over-year, highlighting challenges in the automotive sector [12]. - BYD announced the launch of its Tian Shen Zhi Yan 5.0 advanced driver assistance system, which incorporates the latest large model version and claims to enhance driving stability and response times [13]. - The automotive sector's performance is under scrutiny, with the A-share automotive index underperforming the Shanghai Composite Index, indicating potential challenges in the market [11][14]. Group 3 - The report discusses the significant outflow from broad-based ETFs, with a net outflow of 316.754 billion yuan, while sectors like non-ferrous metals and basic chemicals saw net inflows, indicating a shift in investor sentiment [16][17]. - The macroeconomic environment remains balanced but cautious, with the central bank conducting substantial reverse repos and medium-term lending facility operations, impacting short and long-term interest rates [16][17]. - The report emphasizes the need for investors to be aware of the potential for market volatility and the importance of monitoring central bank actions and economic indicators [16][17]. Group 4 - The service consumption policy has been strengthened, with the government promoting initiatives to enhance service consumption in sectors such as transportation, tourism, and home services, which is expected to boost economic activity [18][19]. - Companies in the human resources service sector, such as Core International, are projected to see significant growth in net profit, driven by increased demand for talent due to technological innovation and industry integration [20]. - The tourism sector is also expected to benefit from the upcoming holiday season, with companies like Three Gorges Tourism forecasting a decline in net profit due to tax payments and asset impairments, indicating challenges in the sector [21]. Group 5 - ASML reported a Q4 2025 revenue of €9.718 billion, with a net profit of €2.840 billion, and a significant order value of €13.158 billion, indicating strong demand for its products [24][25]. - The company anticipates a revenue range of €34-39 billion for 2026, driven by robust demand for logic and DRAM products, particularly in the EUV segment [26]. - ASML's optimistic outlook is supported by its strong order book and the expected growth in the semiconductor market, particularly in advanced manufacturing processes [26][27]. Group 6 - Wanchen Group is projected to achieve a revenue of 50-52.8 billion yuan in 2025, reflecting a year-over-year growth of 54.7%-63.3%, with net profit expected to increase significantly [28][29]. - The company is expanding its store network, with an estimated 18,000 stores by the end of 2025, and is focusing on enhancing its supply chain and operational efficiency to improve profitability [30][31]. - The report indicates that Wanchen Group's strong performance is attributed to its strategic focus on core competencies and the effective management of its supply chain and logistics [31][32].

Investment Rating - The report assigns a "Buy" rating for the company, marking its first coverage [2][8]. Core Insights - The company is accelerating its overseas clinical trials for the drug SSGJ-707, with a significant upfront payment of 2.89 billion RMB from Pfizer, contributing to an expected total revenue of 9.63 billion RMB from this authorization in 2025 [6][7]. - Pfizer has initiated the first patient enrollment for the Phase III clinical trial of SSGJ-707 targeting mCRC, marking a significant milestone as the first MRCT Phase III trial conducted by a multinational corporation in the PD-1/VEGF field [7]. - The company has a rich pipeline with multiple catalysts expected in 2026, including the anticipated approval of three new molecular entities and the ongoing progress of global Phase III clinical trials for SSGJ-707 [7]. Financial Projections - Revenue projections for the company are estimated at 19.216 billion RMB for 2025, with a growth rate of 111%, followed by 11.085 billion RMB in 2026, reflecting a decline of 42%, and a recovery to 12.906 billion RMB in 2027, with a growth rate of 16% [9][10]. - The net profit attributable to the parent company is projected to be 10.967 billion RMB in 2025, with a significant increase of 425%, followed by a decrease to 2.443 billion RMB in 2026, and an increase to 3.411 billion RMB in 2027 [9][10]. - The report anticipates a price-to-earnings (P/E) ratio of 4.8x for 2025, 21.6x for 2026, and 15.4x for 2027, indicating a potential for valuation adjustments as new products are launched [9][10].

Market Overview - The market is transitioning from strong expectations to a "data verification" phase as the Spring Festival approaches, with a focus on marginal improvements in fundamental data[3] - Southbound capital continues to flow into the market, supporting Hong Kong stocks, which are expected to experience a "stock-heavy, index-light" structural market[3] Key Variables for February - Attention will be on post-Spring Festival consumption data, including tourism, dining, and real estate sales, which may reflect the effectiveness of the "resident income increase plan" and domestic demand expansion[4] - The upcoming "Two Sessions" will provide insights into fiscal policies, particularly regarding long-term special bonds and "new productivity," which could influence market sentiment towards infrastructure and technology sectors[4] - The market's confidence in the Fed's interest rate cuts may be affected by resilient U.S. inflation data, necessitating close monitoring of the dollar index's impact on Hong Kong stock liquidity[4] Sector Focus - Consumer and internet sectors are expected to benefit from positive Spring Festival data, with a focus on policy-driven areas like hospitality and food and beverage[5] - Hard technology and overseas manufacturing sectors are promising, particularly in semiconductors and consumer electronics, as well as leading companies in engineering machinery and home appliances[5] - Upstream resource products, such as copper and aluminum, are anticipated to perform well due to a recovering global manufacturing PMI and post-holiday inventory replenishment expectations[5] Stock Recommendations - **Cheung Kong Property Trust (778HK)**: Target price of HKD 5.92, potential upside of 15.9%, with a strong dividend yield over 7%[9] - **NVIDIA (NVDAUS)**: Target price of USD 245.00, potential upside of 27.3%, driven by sustainable AI demand[13] - **Hesai Technology (2525HK)**: Target price of HKD 269.66, potential upside of 35.0%, benefiting from L3 autonomous driving advancements[20] - **Sangfor Technologies (1530HK)**: Target price of HKD 39.50, potential upside of 65.1%, with strong growth prospects from core products[27] - **Midea Group (000333CH)**: Target price of HKD 96.20, potential upside of 23.5%, supported by robust market leadership and dividend policies[32] - **GCL-Poly Energy (3800HK)**: Target price of HKD 1.54, potential upside of 37.5%, benefiting from developments in perovskite technology and commercial aerospace[38]